An Open-Label, Multicenter, Expanded Access Study of Oral AMN107 in Adult Patients With Imatinib (Glivec/Gleevec) - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase.

Trial Profile

An Open-Label, Multicenter, Expanded Access Study of Oral AMN107 in Adult Patients With Imatinib (Glivec/Gleevec) - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ENACT
  • Sponsors Novartis
  • Most Recent Events

    • 09 Nov 2009 Status of parent trial changed from active, no longer recruiting to completed, according to ClinicaTrials.gov
    • 09 Nov 2009 Status of parent trial changed from active, no longer recruiting to completed, according to ClinicaTrials.gov
    • 18 Dec 2007 Status of parent trial changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top